All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
2018 — 9 Books and Research Papers Citing DrugPatentWatch
Da Veiga, C. R. P., Da Veiga, C. P., & Del Corso, J. M. (2018). More Than One Decade Of Viagra: What Lessons Can Be Learned From Intellectual Property Rights In The Erectile Dysfunction Market? In Intellectual Property to Promote Innovation (pp. 123-145). World Scientific.
This chapter examines the evolution of Viagra's patent portfolio over more than a decade, utilizing DrugPatentWatch data to analyze patent expirations, exclusivity periods, and market dynamics. The authors discuss the implications of patent strategies on generic entry and market competition in the erectile dysfunction segment.
Garcia, C. A., & Stroud, J. (2018). Ships in the Night: Resolving Administrative Conflict Between FDA-and Patent-Related Legislation. American University Law Review, 67(4), 1235-1270.
The article explores conflicts between FDA regulations and patent laws, with insights drawn from DrugPatentWatch's patent data. It highlights how discrepancies between regulatory and patent timelines can affect drug availability and market entry, proposing legal reforms to harmonize these systems.
Diao, S. (2018). From American Acts to CPTPP Rules: The Enlightenment to Patent Linkage Reforms in China. In Proceedings of the International Conference on Judicial, Administrative and Humanitarian Problems (pp. 89-102). Atlantis Press.
This paper discusses China's patent linkage system in the context of international trade agreements, referencing DrugPatentWatch for comparative analysis. It assesses the effectiveness of patent linkage in balancing innovation incentives and generic drug access.
Jordan, C. J., & Xi, Z. (2018). Discovery and Development of Varenicline for Smoking Cessation. Expert Opinion on Drug Discovery, 13(5), 467-478.
The authors trace the development of varenicline, using DrugPatentWatch to examine patent filings and exclusivity periods. They analyze how intellectual property strategies influenced the drug's market entry and the availability of generic alternatives.
Mayank, S., & Suhani, S. (2018). Precision Medicine as a Promising Tool to Empower Research in Healthcare Industry. GSC Biological and Pharmaceutical Sciences, 7(2), 45-58.
This article discusses the role of precision medicine in healthcare, referencing DrugPatentWatch to illustrate how patent data can inform research and development strategies. It emphasizes the importance of intellectual property management in advancing personalized therapies.
European Commission. (2018). Study on the Economic Impact of Supplementary Protection Certificates, Pharmaceutical Incentives and Rewards in Europe. Health and Food Audits and Analysis.
This report assesses the economic impact of supplementary protection certificates (SPCs) in Europe, utilizing DrugPatentWatch data to evaluate patent term extensions and their effects on market competition. It provides policy recommendations for balancing innovation and access.
Dai, Y. (2018). The Commercialization of a Novel Antithrombotic Drug. Case Western Reserve University.
Dai's case study on the commercialization of a new antithrombotic drug utilizes DrugPatentWatch to analyze patent landscapes and market exclusivity. The study provides insights into strategic decisions regarding patent filings and market entry.
Hernández, R. G., & Gibert, M. C. (2018). Fuentes de Información de Patentes y Procedimiento para las Búsquedas de Libertad de Acción en Cuba. Revista Cubana de Información en Ciencias de la Salud, 29(3), 234-245.
This paper outlines patent information sources and freedom-to-operate search procedures in Cuba, citing DrugPatentWatch as a valuable tool for accessing global patent data. It discusses methodologies for assessing patent risks in drug development.
Tsomartova, F. V. (2018). Государственные гарантии доступности лекарственных средств в России и за рубежом. Журнал зарубежного законодательства и сравнительного правоведения, 6(2), 112-125.
Tsomartova examines government guarantees for drug accessibility in Russia and abroad, referencing DrugPatentWatch to analyze patent expiration trends and their impact on drug availability. The study compares international approaches to patent term extensions and generics.
